目的分析青中年和老年急性眩晕发作的病因分布及治疗转归。方法收集急性眩晕发作患者208例,包括青中年组98例和老年组110例。采集病史并完成体查后,患者行急诊头颅CT检查。排除出血且未进行溶栓治疗者,均予血小板、调脂、扩血管、改善循环、解除血管痉挛、抗眩晕等治疗,并在7d内完成相应检查以明确诊断。结果两组眩晕患者病因构成差异有统计学意义(P<0.05)。青中年组以周围性眩晕最常见(48.0%),老年组以中枢性眩晕最常见(59.1%)。但青中年组中,中枢性眩晕亦仍占较大比例(27.6%)。排除出血且未进行溶栓治疗者(青中年组95例,老年组105例)中,治疗7d内多数患者症状均获得完全缓解,两组间缓解率差异无统计学意义(P>0.05);两组均无患者出现出血并发症。结论青中年与老年急性眩晕病因分布虽存在一定差异,但青中年中枢性眩晕,尤其血管源性眩晕患者亦较多。考虑抗血小板等治疗方案较为安全,为避免延误治疗时机,对无法完全排除缺血性脑血管病的患者建议早期按照缺血性脑卒中治疗。 Objective To analyze the etiological distribution and treatment outcome of acute middle-aged and elderly patients with vertigo. Methods 208 patients with acute vertigo were collected, including 98 middle-aged and middle-aged patients and 110 elderly patients. After collecting the medical history and completing physical examination, the patient underwent emergency head CT examination. Excluding bleeding and not thrombolytic therapy were given to platelets, lipid-lowering, vasodilation, improve circulation, relieve vasospasm, anti-dizziness and other treatment, and within 7d to complete the appropriate examination to confirm the diagnosis. Results There were significant differences in etiology between the two groups (P <0.05). Middle-aged patients with peripheral vertigo were the most common (48.0%) in the middle-aged group, and vertigo was the most common in the elderly group (59.1%). However, young middle-aged group, central vertigo also accounted for a large proportion (27.6%). Among the 95 patients in the middle-aged group and 105 in the elderly group, the symptoms of most patients were completely relieved within 7 days after treatment. There was no significant difference in remission rate between the two groups (P> 0.05) No bleeding complications occurred in either group. Conclusion There are some differences in the distribution of the etiology of acute vertigo between young and middle-aged adults, but there are more patients with central vertigo in young and middle-aged, especially those with vertigo. Consider the anti-platelet and other treatment options more secure, in order to avoid delays in the timing of treatment, can not completely rule out ischemic cerebrovascular disease in patients with early recommendations according to ischemic stroke treatment.